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Disruption of Golgi α-mannosidase II activity 
can result in type II congenital 
dyserythropoietic anemia and can induce 
lupus-like autoimmunity in mice. Here, we 
isolate a mutant human embryonic kidney 
(HEK) 293T cell line, called Lec36, that 
displays sensitivity to ricin that lies between 
the parental HEK 293T cells, whose secreted 
and membrane-expressed proteins are 
dominated by complex-type glycosylation, and 
293S Lec1 cells, which only produce 
oligomannose-type N-linked glycans. The stem 
cell marker, 19A, was transiently expressed in 
the HEK 293T Lec36 cells, and in parental 
HEK 293T cells with and without the potent 
Golgi α-mannosidase II inhibitor, swainsonine. 
Negative-ion nano-electrospray ionization 
mass spectra of the 19A N-linked glycans from 
HEK 293T Lec36 and swainsonine-treated 
HEK 293T cells were qualitatively 
indistinguishable and, as shown by 
collision-induced dissociation spectra, 
dominated by hybrid-type glycosylation. 
Nucleotide sequencing revealed mutations in 
each allele of MAN2A1, the gene encoding 
Golgi α-mannosidase II: a point mutation in 
one allele mapping to the active site and an 
in-frame deletion of twelve-nucleotides in the 
other. Expression of wild-type but not the 
mutant MAN2A1 alleles in Lec36 cells restored 
processing of the 19A reporter glycoprotein to 
complex-type glycosylation. The Lec36 cell line 
will be useful for expressing therapeutic 
glycoproteins with hybrid-type glycans and 
provides a sensitive host for detecting 
mutations in human MAN2A1 causing type II 
congenital dyserythropoietic anemia.  
 Mammalian N-linked glycosylation is 
characterized by significant chemical 
heterogeneity generated by an array of competing 
glycosidases and glycosyltransferases (1). The 
structural analysis of recombinant glycoproteins, 
such as human erythropoietin (2,3), has 
illustrated the capacity of mammalian expression 
systems for generating diverse N-linked glycans. 
 Heterogeneity develops during egress of a 
glycoprotein through the secretory system (1). 
N-linked glycosylation is initiated in the rough 
endoplasmic reticulum (ER), by the 
co-translational transfer of Glc3Man9GlcNAc2 to 
the asparagine residues of the glycosylation 
sequon. In the absence of protein mis-folding, 
hydrolysis by ER α-mannosidase I plus 
α-glucosidase I and II results in the transfer of 
glycoproteins dominated by the D1,D3 isomer of 
Man8GlcNAc2 glycans to the Golgi apparatus (4). 
Further processing by Golgi α-mannosidases 
IA−C generates Man5GlcNAc2 (5-7), the 
principle substrate for 
UDP-N-acetyl-D-glucosamine:α-3-D-mannoside 
β1,2-N-acetylglucosaminyltransferase I (GnT I). 
The action of this enzyme yields classic 
hybrid-type glycans with mannosyl 6-antennae 
and processed 3-antennae (1). In the absence of 
GnT III-mediated addition of bisecting GlcNAc, 
the two terminal α-mannose residues of the 
6-antenna of hybrid-type glycans are cleaved by 
Golgi α-mannosidase II, forming 
mono-antennary complex-type glycans. These 
may then be processed by 
N-acetylglucosaminyltransferases, generating 
multiantennary complex-type glycans of 
enormous potential heterogeneity following the 
sequential transfer of monosaccharides such as 
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 galactose, N-acetylgalactosamine, fucose, and 
N-acetylneuraminic acid (8). 
 The importance of this carbohydrate 
diversity in metazoan biology is illustrated by the 
disease phenotypes that manifest when the 
biosynthesis of particular glycoforms is 
disrupted. In humans, around twelve congenital 
disorders of glycosylation (CDG) have been 
identified with defects in the biosynthesis of 
N-linked glycans (9). One disorder characterized 
by changes in glycosylation is congenital 
dyserythropoietic anemia type II (HEMPAS; 
hereditary erythroblastic multinuclearity with a 
positive acidified-serum lysis test) (10,11). 
HEMPAS is a heterogenous autosomal recessive 
disorder that renders erythrocytes prone to lysis. 
Although the precise molecular basis of 
HEMPAS remains to be determined, it is 
characterized by either a reduction in β1→4 
galactosyltransferase, GnT II or, in some patients, 
Golgi α-mannosidase II activity (11,12). 
Interestingly, the increase in cell surface terminal 
mannose in mice deficient in Golgi 
α-mannosidase II leads to autoimmunity through 
chronic activation of the innate immune system 
(13,14). 
 Lectin-resistant (Lec) cell lines harbouring 
loss- or gain-of-function mutations affecting the 
biosynthesis of N-glycans have emerged as 
powerful tools for the investigation of these 
disorders (15). For example, genetic 
complementation using Lec2, containing a 
mutation in the cytosine monophosphate-sialic 
acid transporter, was used to identify a novel 
CDG, Type-IIf (16). Lectin-resistant cell lines 
can also be used as hosts to study naturally 
occurring mutations, as in the case of CHO Lec23 
cells used to screen α-glucosidase I mutations in 
CDG Type IIb (17). Other applications of 
lectin-resistant cell lines have included the 
expression of specific glycoforms of therapeutic 
glycoproteins. Manipulating the structure of their 
carbohydrate moieties modulates the 
pharmacological properties of glycoproteins by 
altering their bioactivity, serum half-life, and/or 
tissue tropism (18). For example, 
β-glucocerebrosidase expressed in CHO Lec1 
cells (deficient in GnT I activity) exhibits 
mannosylation and improved macrophage uptake 
for the treatment of Gaucher’s disease (19). 
Lectin-resistant CHO cell lines have also been 
used to improve the crystallizability of 
glycoproteins for structural determination by 
X-ray crystallography (20-24).  
 The expression of therapeutic glycoproteins 
as one or more defined ‘glycoforms’ is essential 
for their optimization and may even be necessary 
to obtain regulatory approval (25). To this end, 
eukaryotic expression systems have been 
developed that allow glycosylation to be 
controlled. Recently, Pichia pastoris-based 
strains with human glycosyltransferases have 
been established, allowing the expression of 
glycoforms with oligomannose-, hybrid- and 
some complex-type glycans (26,27), and even 
sialylated complex-type structures (28). 
However, mammalian expression remains the 
dominant technology in industrial settings, 
presumably because of its reliability for the 
expression of human secreted glycoproteins.  
 Whilst the majority of lectin-resistant cell 
lines have been generated using CHO cells, no 
Golgi α-mannosidase II-deficient CHO cell line 
has thus far been generated (15). Furthermore, 
only one human lectin-resistant cell line, i.e. GnT 
I-deficient (Lec1) human embryonic kidney 
(HEK) 293S cells (29), has been produced. 
Hybrid-type glycosylation has been reported to 
accumulate in ricin-resistant baby hamster kidney 
cells (30,31); however these cells contain a 
reduced but detectable level of cell-surface 
complex-type glycans, consistent with an 
incomplete ablation of Golgi α-mannosidase II 
activity (31). Moreover, the hybrids from one of 
these lines contain a trimannosyl rather than 
pentamannosyl core and appear to be heavily 
influenced by GnT II-deficiency, resulting in the 
formation of what are now commonly called 
monoantennary complex-type glycans (32-34). 
We now describe the isolation of an HEK 293T 
cell line mutated at the MAN2A1 locus and 
deficient in Golgi α-mannosidase II activity, via 




 Chemical mutagenesis of HEK 293T cells 
and isolation of mutants resistant to ricin- HEK 
293T cells (ATCC number CRL-1573) were 
cultured adherently in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma, Poole, Dorset, 
U.K.) supplemented with 10% fetal bovine serum 
(FBS; Sigma, Poole, Dorset, U.K.), L-glutamine 
(Invitrogen, Paisley, U.K.) and 
penicillin-streptomycin-neomycin (Sigma, Poole, 
Dorset, U.K.). Cells were plated out at a density 
of 4 × 106 cells per ml in 75 cm2 T-flasks. After 
incubation at 37˚C for 20 hours (5% CO2), the 
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 medium was replaced with fresh medium (20 ml) 
containing 200 μg/ml ethyl methanesulfonate 
(EMS; Sigma, Poole, Dorset, U.K.). Cells were 
grown in the presence of EMS for 20 hours, 
washed twice with phosphate buffered saline 
(PBS), trypsinized, counted and then stored at 
−80 ˚C. The survival rate after EMS treatment 
was ~50%.  One aliquot of frozen mutagenized 
cells was thawed and plated out at 2 × 105 cells 
per 75 cm2 T-flask and left to expand for 5 days 
(~80% confluence). These cells were then split 
1:10 and grown for a further 2 days. The medium 
was replaced with fresh medium containing either 
1 ng/ml or 10 ng/ml of ricin (laboratory stocks, J. 
Michael Lord, University of Warwick, U.K.). 
Cells were re-fed with this medium every 4 days 
(6 treatments in total) until colonies formed. No 
cells survived multiple treatments with 10 ng/ml 
ricin. Seventy colonies surviving treatment with 
1 ng/ml ricin were expanded to confluence in 
6-well plates in medium containing ricin. The 
colonies were then expanded and maintained in 
medium with no ricin and two vials for each were 
stored in FBS/10% dimethyl sulfoxide (DMSO) 
in liquid nitrogen. 
 Cytotoxicity assays- Cytotoxicity was 
measured as the ability of cells to incorporate 
[35S]-methionine into acid-precipitable material 
after ricin or Pseudomonas exotoxin A (PEx) 
treatment. Ricin resistant cell lines were seeded at 
2 × 104 cells per well in 96-well plates. For initial 
screens, after overnight growth and washing with 
PBS, cells were incubated for 4 hours with 100 μl 
fresh DMEM/FBS (control, untreated cells) or 
with 100 μl DMEM/FBS containing ricin, graded 
in 2-fold dilutions from 10.0 ng/ml to 0.156 
ng/ml. Subsequently, cells were washed twice 
with PBS and incubated in PBS containing 
10 μCi/ml [35S]-methionine (Amersham, U.K.) 
for 1 hour. After washing the cells twice with 
PBS, labeled proteins were precipitated with 
three washes in 5% (w/v) trichloroacetic acid 
(Sigma, Poole, Dorset, U.K), the wells were 
washed twice with PBS and the amount of 
radiolabel incorporated was determined after the 
addition of 200 μl of Optiphase ‘SuperMix’ 
scintillation fluid (Perkin-Elmer, MA, U.S.A.) by 
scintillation counting in a Wallac Micro-Beta 
1450 Trilux counter (Perkin-Elmer, MA, U.S.A.). 
Sensitivity to ricin is defined as the concentration 
(IC50) of ricin required to reduce protein synthesis 
to 50% of that in untreated cells. Having 
established approximate IC50 values, assays on 
selected cell lines were repeated using 2-fold 
dilutions of ricin from 640 ng/ml to 0.16 ng/ml. 
Accurate sensitivity values (IC50) were 
determined using a median effect plot (35). Cell 
lines were also screened for non-selected 
sensitivity to PEx by incubating for 4 hours with 
PEx in DMEM/FBS, graded in 2-fold dilutions 
from 5000 ng/ml to 2.44 ng/ml. 
 Binding and flow cytometry analysis- Ricin 
B chain (RTB) was purchased from Vector 
Laboratories (Burlingame, CA, U.S.A.) and 
labeled with Alexa Fluor-647 dye using an Alexa 
Fluor Protein Labeling Kit (Molecular Probes, 
Eugene, OR, U.S.A.). The labeled RTB 
(RTB-Alexa647) was divided into small aliquots, 
protected from light and stored at −20˚C. 3 × 105 
cells were washed twice with PBS and incubated 
in 100 μl PBS/2 mM NaN3 with a final 
concentration of 10 μg/ml RTB-Alexa 647 on ice 
for 30 minutes. After being washed twice with 2 
ml PBS/2 mM NaN3, cells were resuspended in 
PBS/2 mM NaN3 and kept on ice until being 
subjected to flow cytometry using a 
Becton-Dickinson (San Jose, CA, U.S.A.) 
immunocytometry system. 
 Preparation of cDNA from HEK 293T 
parental cells and HEK 293T Lec36 cells- 2 × 106 
cells were re-suspended in residual medium after 
centrifugation. TRIzol reagent (Invitrogen, 
Paisley, U.K.) was added (1 ml) and cells were 
immediately lysed by repetitive pipetting. The 
homogenized samples were incubated at room 
temperature for 5 minutes. After extraction with 
0.2 ml chloroform and precipitation with 0.5 ml 
isopropanol, the pellet was washed in 75% 
ethanol, and dissolved in 100 μl of RNase-free 
water (Sigma, Poole, Dorset, U.K.). For the 
generation of cDNA by reverse transcription 
polymerase chain reaction (RT-PCR), 10 μl of 
RNA (500 ng/μl) was transferred into an 
RNase-free 0.6 ml microfuge tube with 0.5 ng of 
Oligo(dT)12−18 primer (Invitrogen, Poole, U.K.). 
The mixture was heated at 70˚C for 10 minutes. 
An RT-PCR master mix was generated using 
SuperScriptTM II Reverse Transcriptase kit 
(Invitrogen, Poole, U.K.) and RNasin® RNase 
Inhibitor (Promega, Madison, WI, U.S.A.). The 
RNA/Oligo(dT) mix was cooled at room 
temperature for 5 minutes before addition of 9 μl 
RT-PCR master mix and incubation at 42˚C for 
40 minutes followed by 10 minutes at 90˚C and 5 
minutes on ice. The cDNA product was diluted 1 
in 5 using de-ionized water and stored at −20 ˚C. 
Sequence analysis- For comparing the 
sequences of the MAN2A1 (Golgi α-mannosidase 
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 II) and MAN2A2 (Golgi α-mannosidase IIx) 
genes of HEK 293T and HEK 293T Lec36 cells, 
forward 
(5'-ATGAAGTTAAGCCGCCAGTTCACCG-3'; 
nucleotides 1-25 of Swiss-Prot entry Q16706), 
and reverse 
(5'-TCACCTCAACTGGATTCGGAATGTGC-3'
; nucleotides 3435-3410 of Q16706) primers for 
MAN2A1 and forward 
(5’-ATGAAGCTGAAAAAGCAGGTGACAGT
GTGTG-3’; nucleotides 1-31 of Swiss-Prot entry 
P49641) and reverse 
(5’-CTAACCCAAGCGGAGGCGAAAGGTAG
-3’; nucleotides 3420-3395 of P49641) primers 
for MAN2A2 were used to amplify the coding 
regions of the two genes. The PCR product pools 
were then directly sequenced and the experiment 
was repeated to confirm the sequence traces. The 
MAN2A1 gene from the cDNA of Lec36 cells 
was also cloned into pCR®4-TOPO vector using 
the TOPO TA Cloning Kit for Sequencing 
(Invitrogen Ltd., Paisley, U.K.) in order to obtain 
the sequences of the two MAN2A1 alleles 
separately. Thirty clones were picked and 
sequenced to confirm the mutations found in each 
allele.  
    Assessment of the mRNA expression of 
MAN2A1 and MAN2A2- To compare the relative 
mRNA expression levels of MAN2A1 and 
MAN2A2 in HEK293T cells, PCR analysis was 
performed using serial dilutions (neat, 1/4, 1/16, 
1/64 and 1/256) of cDNA prepared from HEK 
293T cells. The coding regions of the two genes 
were amplified by the primers described above.      
 Cloning of cDNA fragments for expression- 
A cDNA fragment encoding the human s19A 
extracellular region (residues 1−222) was 
amplified by polymerase chain reaction (PCR) 
and inserted into the pEE14 vector (36,37) in 
frame with a C-terminal LysHis6 tag.  For the 
complementation experiments involving the 
co-expression of wild type or mutant Golgi 
α-mannosidase II with s19A, the wild type 
MAN2A1 sequence from HEK 293T cells and the 
mutant alleles from HEK 293T Lec36 cells 
cloned into the TOPO TA vector as described 
above were each transferred to the pLEXm 
expression vector (38). In the process, a Kozak 
sequence (gcc acc) was inserted at the 5'- end of 
the cDNA adjacent to the start codon (atg) of the 
Golgi α-mannosidase II gene. The sequences 
were confirmed by dideoxy sequencing. 
 Large-scale expression of s19A in HEK 
293T and HEK 293T Lec36 cells- HEK 293T and 
HEK 293T Lec36 cells were grown to 90% 
confluence and transiently transfected with 
pEE14/s19A using polyethyleneimine (39), and 
the medium immediately replaced with 
DMEM/2% FBS. When used, swainsonine 
(Toronto Research Chemicals, North York, 
Ontario, Canada) was added immediately after 
transfection to a final concentration of 20 μM. 
Conditioned media, containing the secreted 
fusion protein, were collected 4 days 
post-transfection, centrifuged, sterile-filtered and 
diluted with two volumes of PBS. The pH was 
adjusted to 8.0 with 1 M Tris-HCl. The 
His-tagged protein was incubated with 
Ni2+-charged chelating Sepharose (Amersham 
Biosciences, Uppsala, Sweden) at 16˚C for 4 
hours. The beads were then packed in BioRad 
Econo columns, washed with 20 bed volumes of 
PBS/10 mM Tris-HCl pH 8 supplemented with 
0.05% Tween-20 followed by 20 bed volumes of 
PBS/10 mM Tris-HCl pH 8. Bound proteins were 
eluted in 500 mM imidazole/PBS pH 8 and 
concentrated to ~300 μl for Sephacryl S-200 gel 
filtration in 10 mM HEPES pH 7.4, 150 mM 
NaCl. Fractions containing the target protein at 
>95% purity (assessed by SDS-PAGE), were 
pooled, quantified and stored at 4˚C. 
 Complementation experiments in HEK 293T 
Lec36 cells- HEK 293T Lec36 cells were 
co-transfected at about 40% confluence using 
Novagen GeneJuice® (Merck Chemical Ltd, 
Beeston, UK), with an 8:1 molar ratio of s19A 
and either wild-type or allele 1 or allele 2 of 
mutant Golgi α-mannosidase II.  Twelve hours 
post-transfection, the medium was replenished, 
and 2 days post-transfection, the conditioned 
growth medium was harvested by centrifugation 
(6300g, 15 minutes).  s19A was purified from 
the supernatant using Ni2+-charged chelating 
Sepharose as described above. The activities of 
the wild-type and mutant forms of Golgi 
α-mannosidase II were evaluated by testing the 
endoglycosidase H (Endo H) sensitivity of 
purified, co-expressed s19A and by MALDI-TOF 
MS analysis of the sugars released from s19A. 
Endo H sensitivity- The purified proteins 
were treated with Endo H (New England Biolabs, 
Hitchin, UK). Seven micrograms of each protein 
was digested at 37˚C with 1,000 units of Endo H 
in a final volume of 25 μl of 0.1 M NaOAc at pH 
5.2. For comparison, proteins were also treated 
with PNGase F (New England Biolabs, Hitchin, 
UK). Five micrograms of proteins was digested at 
37˚C with 500 units of PNGase F at pH 7.4. The 
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 extent of digestion was monitored by SDS-PAGE 
analysis. Sampling after 1.5 h and 3 hrs of 
digestion confirmed that it had gone to 
completion within 1.5 hr.   
 Enzymatic release of N-linked glycans- 
Oligosaccharides were released from bands 
containing approximately 10 μg of s19A excised 
from Coomassie blue-stained reducing 
SDS-PAGE gels, which were washed with 20 
mM NaHCO3 pH 7.0 and dried in a vacuum 
centrifuge, by rehydration with 30 μl of 30 mM 
NaHCO3 pH 7.0 containing 100 Units/ml of 
PNGase F (Prozyme, San Leandro, California, 
U.S.A.) and incubation for 12 hours at 37˚C (40). 
The enzymatically released N-linked glycans 
were eluted with water. Salts were removed by 
incubation at approximately 24˚C (5 minutes) 
with 200 μl of acid-activated AG-50W (200−400 
mesh) slurry (BioRad, Hercules, California, 
U.S.A.) which was removed by filtration with a 
0.45 μl pore-size filter (Millex-LH, hydrophobic 
polytetrafluoroethylene). 
 Matrix-assisted laser desorption/ionization 
(MALDI) time-of-flight (TOF) mass 
spectrometry- Aqueous solutions of the glycans 
were cleaned with a Nafion 117 membrane (41). 
Positive ion MALDI-TOF mass spectra were 
recorded with a Waters-Micromass TofSpec 
reflectron-TOF mass spectrometer 
(Waters-Micromass MS Technologies Ltd., 
Manchester, U.K.) fitted with delayed extraction 
and a nitrogen laser (337 nm). The acceleration 
voltage was 20 kV; the pulse voltage was 3200 
V; and the delay for the delayed extraction ion 
source was 500 ns. The spectra in Figure 7 were 
recorded with a Waters MALDI Micro MS mass 
spectrometer with an extraction voltage of 12 kV. 
Samples were prepared by adding 0.5 μl of an 
aqueous solution of the sample to the matrix 
solution (0.3 μl of a saturated solution of 
2,5-dihydroxybenzoic acid in acetonitrile) on the 
stainless steel target plate and allowing it to dry at 
room temperature. The sample/matrix mixture 
was then recrystallized from ethanol.  
 Electrospray ionization (ESI) mass 
spectrometry- Electrospray mass spectrometry 
was performed with a Waters-Micromass 
quadrupole-time-of-flight (Q-Tof) Ultima Global 
instrument in negative ion mode. Samples in 1:1 
(v:v) methanol:water were infused through 
Protana (Protana, Odense, Denmark) borosilicate 
nanospray capillaries. The ion source conditions 
were: 120˚C; nitrogen flow 50 l/hr; infusion 
needle potential, 1.2 kV; cone voltage 100 V; 
RF-1 voltage 150 V. Spectra (2 sec scans) were 
acquired with a digitization rate of 4 GHz and 
accumulated until a satisfactory signal:noise ratio 
had been obtained. The ions were observed as 
[M+H2PO4]- adducts, the phosphate arising from 
residual phosphate in the solution. For MS/MS 
data acquisition, the parent ion was selected at 
low resolution (about 5 m/z mass window) to 
allow transmission of isotope peaks and 
fragmented with argon at a pressure (recorded on 
the instrument’s pressure gauge) of 0.5 mBar. 
The voltage on the collision cell was adjusted 
with mass and charge to give an even distribution 
of fragment ions across the mass scale (typically 
80−120 V). Other voltages were as recommended 
by the manufacturer. Instrument control, data 
acquisition and processing were performed with 
MassLynx software Version 4.0 
(Waters-Micromass MS Technologies Ltd., 
Manchester, U.K.). The negative ion 
collision-induced dissociation (CID) spectra 
provide highly diagnostic fragmentation spectra 
that enable structural assignment of the glycans. 
For a more extensive discussion of these 
techniques, see Harvey et al. (42-45). 
   
RESULTS AND DISCUSSION 
 
 Selection strategy. HEK 293T cells were 
chosen for selection with ricin owing to their 
recent emergence as a host for large-scale 
production of human glycoproteins for structural 
and functional analysis. Ricin is a heterodimeric 
toxin, comprising a toxic A chain (RTA) that 
depurinates a specific base on the 28S rRNA, 
disulphide-linked to a cell binding B chain (RTB) 
with specificity for terminal β1→4 linked 
galactose residues (46). Following cell binding 
and endocytosis, the holotoxin traffics in a 
retrograde manner, via early endosomes and the 
trans-Golgi network, to the ER [(47), and 
references therein]. In the ER, the toxin is 
processed and reductive separation of RTA and 
RTB occurs (48). RTA then retrotranslocates 
(dislocates) to the cytosol, where scrutiny by the 
Hsc70 and Hsp90 chaperones leads to recovery of 
catalytically active toxin that depurinates rRNA, 
blocking protein synthesis and, ultimately, 
inducing cell death (49).  
 Ricin resistance could, in principle, result 
from mutations of genes controlling retrograde 
trafficking, ER processing, dislocation and 
cytosolic processing of the toxin or of genes that 
alter the glycosylation of proteins functioning as 
ricin receptors. Following selection, therefore, we 
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 screened our ricin-resistant HEK 293T cells for 
non-selected resistance to Pseudomonas exotoxin 
A (PEx), which also traffics in a retrograde 
manner to the ER, and whose A chain also 
dislocates to the cytosol [(47), and references 
therein], in order to eliminate mutations generally 
affecting trafficking, toxin processing and 
dislocation. Screens of ricin binding-site 
expression, ability to support high-level 
expression of transfected genes and 
electrophoretic analysis of the glycoprotein 
products of the transfected genes were then used 
to refine our search for a stable, viable Golgi 
α-mannosidase II-deficient cell line. 
 Isolation of ricin-resistant HEK 293T 
mutants. Lectin-resistant HEK 293T cells were 
generated using the method of Reeves et al. who 
derived the HEK 293S Lec1 cell line (29). 
Briefly, EMS-mutagenized HEK 293T cells were 
grown in the presence of 1 ng/ml or 10 ng/ml 
ricin, and single cell-derived colonies were 
obtained after three weeks at a ricin concentration 
of 1 ng/ml. Although Reeves et al. selected 293S 
cell-derived clones deficient in GnT I activity in 
medium containing 10 ng/ml ricin (29), under the 
conditions of our experiments, no 
EMS-mutagenized cells survived such a 
challenge.  To examine this further, we grew the 
GnT I-deficient HEK 293S Lec1 cells in the 
presence of two rounds of 15.6, 7.8, 3.9, 1.9 and 
0.9 ng/ml ricin. At 15.6 ng/ml and 7.8 ng/ml ricin, 
all Lec1 cells died after one round of treatment. 
At 3.9 ng/ml ricin, only a few cells survived after 
the two rounds of ricin treatment and at the end 
of the experiment, there was only one surviving 
colony comprising ~100 vacuolated cells that 
were not growing. At concentrations of 1.9 and 
0.9 ng/ml, about seventy and >200 viable 
colonies grew, respectively. We are therefore 
confident that under our conditions, even 293S 
Lec1 cells cannot survive challenge with 10 
ng/ml ricin. The difference between the apparent 
sensitivities of Lec1 cells in the two laboratories 
may simply reflect differences in the specific 
activity of the ricin used.  
 Screening of ricin-resistant HEK 293T 
mutant cell lines. Screen 1: Ricin sensitivity.  
From the original set of EMS-mutagenized, HEK 
293T-derived clones, we collected seventy that 
survived six rounds of challenge with 1 ng/ml 
ricin and expanded these clones into lines in the 
absence of ricin. The cell lines were initially 
screened in a cytotoxicity-based, ricin-sensitivity 
assay (Fig. 1A, Table I). Three cell lines (coded 
green) were approximately 20-fold resistant to 
ricin compared to parental HEK 293T cells 
(coded dark blue), and thus had cytotoxicity 
resistance profiles matching that of 293S Lec1 
cells (open circles and dotted line). The 
remainder of the clones exhibited 2- to 12-fold 
variation in resistance. 
 Screen 2: PEx sensitivity.  All the cell lines 
were screened for sensitivity to PEx (Fig. 1B, 
Table I). Six of these (coded orange) showed ~5 
to 9 fold non-selected resistance to PEx and 2−9 
fold ricin resistance versus HEK 293T cells (Fig. 
1B,C, Table 1), suggesting that these cell lines 
carry mutations in gene(s) whose products limit 
the toxicity of both toxins. Candidate disruptions 
could involve (a) retrograde trafficking 
machineries, since both ricin and PEx traffic from 
the cell surface via the trans-Golgi network to the 
endoplasmic reticulum (ER), (b) ER-processing, 
since the A chain of each toxin is separated from 
its cell-binding B partner in the ER, (c) 
dislocation systems that permit the 
retrotranslocation of the A chain into the cytosol 
and (d) cytosolic processing events. 
 Screen 3: Ricin B chain binding.  Ricin 
binds mammalian cells primarily through 
interactions of its B chain with exposed terminal 
β1→4 linked galactose residues. To estimate the 
relative number of ricin binding sites, most of the 
cell lines were tested by flow cytometry analysis 
using a fluorescent ricin B chain probe (Fig. 1D, 
Table I). Highly ricin-resistant cells (green) 
display the much-reduced RTB binding 
characteristic of 293S Lec1 cells, and were not 
characterized further. The remaining clones 
cluster into two broad groups, one (I) with close 
to parental (blue) numbers of RTB-binding sites 
and the other (II) with reduced RTB-binding. 
Most of the cell lines with high PEx resistance 
(orange) cluster in the former group, with close to 
normal numbers of ricin binding sites, consistent 
with the notion that these do not carry mutations 
in ricin receptors. Group I cell lines were not 
examined any further. Group II cell lines have 
reduced numbers of ricin-binding sites, and it was 
from within this set that we expected to identify 
novel glycosylation mutations. 
 Screen 4: High-level expression of 
transfected cell-surface molecules.  Group II 
cell lines were transiently transfected with a 
pEE14 plasmid encoding the soluble (s) 
extracellular region of the stem-cell marker, 19A. 
Supernatants from these cultures were then 
screened by Western blot for high-level 
expression of s19A (data not shown). Cells 
capable of high-level expression of s19A were 
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 selected, and the s19A purified. Three cell lines 
(Fig. 1, plum) expressed s19A with an apparent 
molecular weight 5−10 kDa larger than that of 
s19A produced in 293S Lec1 cells.  Of these, 
one was selected for further study and, following 
the nomenclature of Patnaik and Stanley (15), is 
hereafter designated HEK 293T Lec36. 
 Characterization of Lec36 cells. Parental 
HEK 293T cells, GnT I-deficient 293S Lec1 cells 
and HEK 293T Lec36 cells were re-tested for 
ricin sensitivity. Parental HEK 293T cells are 
very sensitive to ricin with an IC50 (the ricin 
concentration that inhibits protein synthesis by 
50% versus untreated cells) of 1.69 ± 0.46 ng/ml 
(1 S.D., n = 7) whereas HEK 293T Lec36 cells 
were highly resistant [IC50 = 13.02 ± 0.77 ng/ml 
(1 S.D., n = 3]. This is about half the resistance of 
GnT I-deficient 293S cells [IC50 of 28.21 ± 5.39 
ng/ml (1 S.D., n = 3)]. Since ricin binds terminal 
β1→4 linked galactose residues, this intermediate 
sensitivity suggests that these cells have a 
disruption in the glycosylation pathway differing 
from that of Lec1 cells. The levels of 
ricin-resistance were mirrored in the flow 
cytometric analysis where ricin B chain binding 
for HEK 293T Lec36 cells fell between that for 
the parental HEK 293T cells and GnT I-deficient 
(Lec1) 293S cells (Fig. 2A).  
 So that putative changes in glycan 
processing could be examined directly, HEK 
293T Lec36 cells were transiently transfected 
with a pEE14 plasmid encoding the s19A 
glycoprotein. The s19A glycoprotein was 
selected as a reporter molecule for glycosylation 
as it contains six N-linked glycosylation sequons 
distributed over two immunoglobulin domains 
and consequently changes in glycan processing 
can be readily assessed by Endo H digestion and 
SDS-PAGE (23). In addition to HEK 293T 
Lec36, s19A was also expressed in 293S Lec1 
cells, parental HEK 293T cells and in HEK 293T 
cells in the presence of 20 μM swainsonine, 
giving yields of 1.6, 2.2, 5.4 and 6.0 mg/l, 
respectively. Variation in apparent molecular 
weight according to SDS-PAGE analysis (Fig. 
2B) can be attributed to the N-linked glycans as 
all variation between the samples is eliminated by 
digestion with protein N-glycanase (PNGase) F 
[data for swainsonine-treated s19A are published 
elsewhere (21)]. GnT I-deficiency in 293S cells 
results in the accumulation of Man5GlcNAc2 
N-glycans [Fig. 2C; (29,50)]. s19A from HEK 
293T Lec36 cells migrated at ~45 kDa whereas 
s19A from the GnT I-deficient 293S cells 
migrated as 35−40 kDa, indicating that Lec36 
glycans are larger than Man5GlcNAc2. The 
presence of hybrid- or oligomannose-type 
glycans on s19A from HEK 293T Lec36 cells 
was confirmed by Endo H digestion (Fig. 2B). 
 Identification of N-linked glycans from 
s19A. The Lec36 N-glycans were further 
characterized by MALDI-TOF (Fig. 3) and 
nano-ESI mass spectrometry (Fig. 4) following 
release from s19A with PNGase F. Importantly, 
glycans were identified not only by composition 
but also by negative ion MS/MS (42-44,51). 
MALDI rather than ESI spectra are shown owing 
to the greater clarity of the spectra resulting from 
the ionization of the glycans as single sodium 
adducts. HEK 293T cells are capable of 
sialylation as observed in the hybrid structures of 
Figure 3B and 3C. The ESI spectra revealed 
slightly higher abundance of sialic acid compared 
to the MALDI spectra due to the differing 
ionization efficiencies. The N-linked glycans 
from s19A expressed in HEK 293T cells were 
predominantly of the complex and 
oligomannose-type with a low abundance of 
hybrid-type glycans (Fig. 3A). The most 
abundant glycan was Man5GlcNAc2 ([M+Na]+ 
m/z = 1257.4).  A series of other 
oligomannose-type glycans, Man6−8GlcNAc2 at 
m/z = 1419.5, 1581.6, 1742.6, were also 
identified. The remaining glycans were 
complex-type, revealing significant Golgi 
α-mannosidase II activity, and exhibited a range 
of elaborations from, for example, a 
monoantennary structure (m/z = 1136.4) to a core 
fucosylated tri-antennary glycan (m/z = 2174.8).  
 In contrast to parental HEK 293T 
cell-derived s19A, the mass spectra for s19A 
expressed in the HEK 293T Lec36 cells or in 
HEK 293T cells in the presence of swainsonine 
(Fig. 3B and 3C, respectively), were completely 
free of complex-type N-glycans. All of the major 
glycans were of the classical Man5 hybrid-type. 
The striking similarity of the two spectra strongly 
implies disruption of Golgi α-mannosidase II 
activity in the HEK 293T Lec36 cells. Negative 
ion fragmentation allowed assignment of all the 
peaks to oligomannose-type or hybrid-type 
structures.  
 We also note that a small population of 
Man4 hybrid-type glycans was released from 
s19A produced under both sets of conditions, for 
example at m/z = 1298.6 (Fig. 3). The presence of 
α-mannosidase activity of unknown origin has 
been previously reported in lectin-resistant cell 
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 lines. CHO Lec1 displays an as yet undetermined 
α-mannosidase activity that digests the dominant 
Man5GlcNAc2 to Man3−4GlcNAc2 (22,50). In 
addition, Golgi α-mannosidase IIx is inhibited by 
swainsonine (52). Given that trace amounts of 
Man4-based hybrids were detected in s19A 
expressed in HEK 293T Lec36 cells and in 
swainsonine-treated 293T cells (Fig. 3B and 3C, 
respectively), this activity is unlikely to be 
attributable to a class II α-mannosidase. 
 Structural assignment of the N-linked 
glycans. The structural assignment of the glycans 
in Figure 3 is based on highly diagnostic 
fragmentation in the negative ion 
collision-induced dissociation (CID) spectra 
(42-44,53). An example of the assignment of ions 
to hybrid-type structures as opposed to isobaric 
complex-type glycans is illustrated in Figure 4 for 
the glycan of composition Hex5HexNAc4dHex1 
(m/z 1883.7). The CID spectrum of the ion from 
s19A expressed in the parental cell line contains 
features characteristic of a core fucosylated 
bi-galactosyl biantennary complex type glycan 
(Fig. 4A). The complex nature of the 6-antenna 
was revealed by the presence of D (containing the 
6-antenna and core-branching mannose) and 
[D-18]- ions at m/z 688.3 and 670.3, respectively 
and the ion at m/z 424 which is a 1,3A cleavage of 
the antenna-mannose residues confirming the 
composition of the antennae as Hex-HexNAc 
[ion nomenclature is as described by Domon and 
Costello (54)]. The C1 ion at m/z 179 confirmed 
hexose (galactose) at the non-reducing terminus 
and the 2,4A6, B6 and 2,4A5 ions at m/z 1478.6, 
1418.6 and 1275.5, respectively, located the 
fucose to the 6-position of the asparagine-linked 
GlcNAc residue. 2,4A and B ions from the core 
GlcNAc residues appeared at the same m/z values 
in the spectrum of the hybrid glycans shown in 
Figure 4B, again indicating the presence of a core 
fucose residue. However, the remainder of the 
spectrum was very different to that shown in 
Figure 4A. The ion at m/z 424 was of very low 
abundance but was replaced by two ions at m/z 
262 and 465 with compositions of HexNAc+59 
and HexNAc2+59 respectively. The C1 ion at m/z 
220 confirmed HexNAc at the non-reducing 
terminus in addition to hexose which gave the 
corresponding ion at m/z 179. The D and [D-18]- 
ions appeared at m/z 647 and 629 and these ions, 
together with the cross-ring products at m/z 575 
and 545, defined a 6-antenna containing three 
hexose (mannose) residues. In summary, the 
spectrum appeared to be that of a mixture of two 
hybrid compounds; the high abundance of m/z 
629 relative to m/z 670 was characteristic of a 
glycan containing a bisecting GlcNAc and was 
consistent with the presence of the HexNAc+59 
(1,3A2β) ion at m/z 262. The second hybrid 
appeared to contain a HexNAc2 chain (probably 
GalNAc−GlcNAc) and accounted for the 
HexNAc2+59 ion at m/z 465.  
 Molecular basis of the Lec36 mutation. The 
observed differences in glycosylation of wild 
type- and HEK 293T Lec36 cell-produced s19A 
were consistent with there being null mutations of 
the Golgi α-mannosidase II gene in the HEK 
293T Lec36 cells. We used reverse 
transcriptase-polymerase chain reaction 
(RT-PCR) to obtain cDNAs from both the cell 
lines and sequenced the PCR products of the 
MAN2A1 and MAN2A2 genes (encoding Golgi 
α-mannosidase II and IIx) from the two cDNAs. 
The sequencing results show that there are two 
mutations in the MAN2A1 gene of the HEK 293T 
Lec36 cells (Fig. 5A). One is a single nucleotide 
mutation, with superimposable traces for G and 
A, resulting in a highly non-conservative 
Gly→Glu mutation at position 574 of the mature 
sequence (using the UniProtKB/Swiss-Prot 
numbering). The second is a deletion of 12 
nucleotides leading to an expected four amino 
acid deletion (1095Ile1096Leu1097Val1098Gln; 
ΔILVQ) in the predicted translation product.  
The sequence is otherwise identical to that 
previously reported (55), except that we observe 
the same polymorphism at residue 608 referred to 
in UniProtKB/Swiss-Prot entry Q16706, wherein 
the codon for this residue in both our sequences 
(parental wild type HEK 293T and HEK 293T 
Lec36 cells) is TTG (Leu) rather than GGG 
(Gly). We proceeded to clone the PCR products 
from the MAN2A1 gene of the HEK 293T Lec36 
cells in order to determine whether the mutations 
affected each allele. The sequencing of 30 clones 
revealed that the mutations are heterozygous. 
Sixteen sequences yielded mutant allele 1 (MA1) 
bearing the point mutation (GGA→GAA; 
G574E) and fourteen sequences yielded the 
second mutation (mutant allele 2, MA2; ΔILVQ), 
wherein twelve nucleotides were deleted. Beyond 
the mutated regions, the sequences of the two 
alleles are identical to that of the parental wild 
type HEK 293T cells. The ease with which the 
bi-allelic null Lec36 mutant was isolated (i.e. 
from 2 x 105 EMS-mutated cells) is somewhat 
surprising given that EMS mutation of the single 
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 functional MgatI allele in Pro-5 CHO cells to give 
Lec1 cells only occurs at a frequency of 10-3 (55). 
 In contrast to MAN2A1, no mutations were 
detected in the MAN2A2 gene of the Lec36 cell 
line, indicating that catalysis by Golgi 
α-mannosidase IIx does not contribute 
significantly to the formation of complex-type 
N-glycans in HEK 293T cells. One possible 
explanation is that Golgi α-mannosidase IIx is 
poorly expressed in HEK 293T cells. Consistent 
with this, MAN2A2 transcripts are substantially 
less abundant (by at least sixty-four fold) in 
cDNA isolated from wild type HEK 293T cells 
than are MAN2A1 transcripts (Fig. S1). 
Wild-type Golgi α-mannosidase II 
restores complex-type glycosylation in HEK 293T 
Lec36 cells. To demonstrate that the Lec36 
mutation disrupts Golgi α-mannosidase II activity 
and to show that the Golgi α-mannosidase II 
deficiency is not due to a mutation in another 
gene that regulates its folding or activity, we 
performed complementation experiments by 
coexpressing s19A as a secreted marker of 
glycosylation alongside the mutated and 
wild-type Golgi α-mannosidases in Lec36 cells. 
s19A expressed alone in HEK 293T cells exhibits 
some Endo H sensitivity (Fig. 6, sample 1) 
consistent with the presence of some 
oligomannose and hybrid-type glycans (Fig. 3A). 
In contrast, s19A expressed alone in HEK 293T 
Lec36 cells is largely Endo H sensitive (Fig. 6, 
sample 2; and as seen above in Fig. 2B). As no 
complex-type glycosylation was detected (Fig. 
3B), the incomplete digestion can be attributed to 
the presence of core fucosylation, which limits 
cleavage by Endo H. In complementation 
experiments using HEK 293T Lec36 cells, 
co-transfection of wild-type, but not the mutant 
MAN2A1 alleles restores glycan processing to 
complex-type forms as assessed by monitoring 
Endo H sensitivity (Fig. 6, samples 3, 4 and 5). 
Expression of the wild-type Golgi α-mannosidase 
II results in glycosylation that is more resistant to 
Endo H than s19A expressed in HEK 293T cells. 
This is consistent with a reduction in the hybrid 
or oligomannose-type glycans, and suggests that 
in HEK 293T cells the activity of Golgi 
α-mannosidase II is limiting for the generation of 
complex glycans. Consistent with this, over 
expression of wild-type Golgi α-mannosidase II 
in HEK 293T cells also reduces the Endo H 
sensitivity of co-expressed s19A (data not 
shown). We note that the Endo H sensitivity of 
s19A expressed in the presence of the mutated 
Golgi α-mannosidase II (either mutant allele 1 or 
mutant allele 2) in HEK 293T Lec36 cells is 
slightly enhanced versus that observed in its 
absence (sample 2 versus sample 4 and 5, Fig. 6). 
s19A is more weakly expressed in the presence of 
the Golgi α-mannosidases (either wild type or 
mutant alleles; data not shown) and the relative 
abundance of the hybrid-type glycans changes 
slightly (Fig. 3B and 7A). Subtle changes in the 
levels or distribution of fucose may account for 
the variation in Endo H sensitivity. The effects of 
the HEK 293T Lec36 mutations on the activity of 
Golgi α-mannosidase II were confirmed with a 
second reporter protein, sPD-L1 (soluble 
Programmed Cell Death 1-Ligand 1; data not 
shown). 
The effects were further investigated 
using MALDI-MS. The MALDI mass spectrum 
of the s19A N-linked glycans reveals that the 
co-expression of wild-type Golgi α-mannosidase 
II results in predominantly complex-type 
glycosylation (Fig. 7A). The low abundance of 
hybrid-type glycans at m/z 1460.6, 1606.6 and 
1622.6, observed in the HEK 293T spectrum 
(Fig. 3A) demonstrates that the over expression 
of wild-type Golgi α-mannosidase II does indeed 
drive the processing of these substrates to 
completion. In contrast, the oligomannose-type 
glycans in the HEK 293T spectrum (Fig. 3A) 
were observed at m/z 1257.5 and 1419.6 
demonstrating that processing upstream of Golgi 
α-mannosidase II was not significantly affected. 
The presence of a greater abundance of tri- and 
tetra-antennary glycans indicates that the 
processing downstream of Golgi α-mannosidase 
II has been stimulated and is consistent with a 
change in the processing kinetics. In contrast to 
the complementation observed with wild-type 
enzyme, the two mutated forms of Golgi 
α-mannosidase II of Lec36 cells fail to restore 
any complex-type glycosylation (Fig. 7B, C), 
demonstrating that the G574E and ∆ILVQ 
mutations each disrupt catalysis. 
 Potential structural effects of the HEK 293T 
Lec36 mutations. In order to consider the 
possible structural effects of the HEK 293T 
Lec36 mutations, we mapped the changes onto 
the structure of Drosophila melanogaster Golgi 
α-mannosidase II, which shares ~40% sequence 
homology with human Golgi α-mannosidase II. 
For this we used both the Drosophila crystal 
structure and sequence alignment of Shah et al. 
(56). The sequence alignment suggests that the 
residue mutated in HEK 293T Lec36 mutant 
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 allele 1 (MA1), i.e. 574Gly, is equivalent to a 
highly conserved residue, 476Gly, that is close to 
the active site of Drosophila Golgi 
α-mannosidase II (Fig. 5B). In the insect 
structure (56), 476Gly forms part of a loop 
containing 472Asp (highlighted in green in Fig. 
5B), that forms critical hydrogen bonds with the 
substrate, in this case the hybrid-type glycan 
GlcNAcβ1→2-Man5GlcNAc2 (shown in yellow 
in Fig. 5B). It can readily be envisaged that the 
G574E mutation would alter the conformation of 
the equivalent loop in human Golgi 
α-mannosidase II, destabilizing substrate binding. 
The deletion in HEK 293T Lec36 allele 2 
(ΔILVQ, MA2), on the other hand, maps to the 
C-terminal region of the α-mannosidase (Fig. 
5B). The corresponding tetrapepetide in the D. 
melanogaster structure, 995Gln996Lys997Leu998Asp 
is adjacent to an α-helix containing a cysteine 
that forms a stabilizing disulfide with a β-strand 
cysteine nine residues towards the C-terminus. 
Sequence conservation in this region is poor and 
the cysteines are not present, but it is possible 
that the ILVQ deletion disrupts analogous 
stabilizing interactions in the human protein.  
 Conclusions. The loss of Golgi 
α-mannosidase II activity in Lec36 cells mimics 
that observed in some patients with HEMPAS 
(10,11). We anticipate that Lec36 cells could find 
application both as a sensitive host for detecting 
mutations in Golgi α-mannosidase II and to 
further investigate the interaction of the altered 
cell surface with the mannose-specific lectins of 
the innate immune system. Although the precise 
molecular basis of HEMPAS remains to be 
determined, it is characterized by either a 
reduction in β1→4 galactosyltransferase, 
GlcNAcTII or Golgi α-mannosidase II activity 
(11,12). In some cases, the alteration in 
oligosaccharide processing may be a secondary 
effect of, for example, changes in enzyme 
localization or membrane trafficking (57). An 
increase in hybrid-type glycosylation has been 
reported in a CDG patient with apparently 
unmutated MAN2A1 and MAN2A2 genes (58), 
perhaps reflecting a defect in the localization of 
Golgi  α-mannosidase II. Indeed, the requirement 
for precise localization of processing enzymes 
became apparent in the re-construction of 
human-like glycosylation in yeast (26,59) and is 
also revealed by the effects of defects in 
intra-Golgi trafficking on glycosylation in cells 
and patients (60,61).  
 Despite the existence of numerous 
lectin-resistant cell lines, the HEK 293T Lec36 
cell line reported herein represents the first 
confirmed Golgi α-mannosidase II-deficient cell 
line. Among several types of applications, 
lectin-resistant cell lines have provided powerful 
tools for the analysis of CDG pathology (15-17), 
and for the manipulation of the oligosaccharide 
chains of glycoprotein therapeutics. The Golgi 
α-mannosidase II -deficient Lec36 cells described 
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 FIGURE LEGENDS 
 
FIGURE 1. Screening of ricin-resistant clones generated by EMS mutagenesis.  (A) Ricin resistance 
of ricin-selected cell lines.  Individual cell lines were treated with graded doses of ricin for 4 hours 
and their subsequent ability to synthesise proteins was determined.  Blue, parental HEK 293T (n = 
24); open circles and dotted lines, HEK 293S Lec1 (n = 4); grey (n = 1 to 4), orange (n = 1, 2, 3 or 6), 
plum (n = 1 to 3) and green (n = 6 or 7), cell lines belonging to various selection screen-defined 
classes. Error bars have been omitted for clarity. (B) Non-selected sensitivity of all of these cell lines 
to Pseudomonas exotoxin A (PEx). Cell lines were treated with graded doses of PEx for 4 hours and 
their subsequent ability to synthesise proteins was determined. Blue (n = 10), open circles (n = 2), 
grey (n = 1 to 4), plum (n = 1 or 3) and green (n = 3) as in A; orange (n = 1 to 5), cells with 
approximately 5-fold or greater resistance to PEx. Error bars have been omitted for clarity. (C) 
Scatter plot of PEx resistance versus ricin resistance for all the cell lines generated. Sensitivity of the 
cell lines to toxin was determined in A by measuring the concentration (IC50, ng/ml) of toxin required 
to reduce protein synthesis to 50% of that of untreated cells, and (fold) resistance was calculated from 
the ratio of the IC50 for the cell line versus the IC50 for HEK 293T cells. PEx resistant cells (orange) 
cluster as a group with 2−9-fold ricin resistance; green, a cluster of cell lines with very high ricin 
resistance. (D) Scatter plot of relative number of ricin B chain-binding sites versus ricin resistance for 
62 of the cell lines generated (seven “grey” and one “green” cell line were not tested). The relative 
number of ricin binding sites on the cell lines was determined by flow cytometry using Alexa 
647-labeled ricin B chain. Apart from the highly ricin-resistant lines (green), the cell lines cluster into 
two broad groups, with either medium to high (Group I) or low to medium (Group II) numbers of 
ricin-binding sites. Plum-coloured symbols, candidate HEK 293T Lec36 cells.  
 
FIGURE 2. Identification of Lec36 cells. (A) Flow cytometric analysis of HEK 293S Lec1, Lec36 
and parental HEK 293T cells using Alexa 647-labeled ricin B. (B) Endo H sensitivities of s19A 
expressed in HEK 293S Lec1, HEK 293T Lec36 and HEK 293T cells analyzed by SDS-PAGE 
(undigested, and Endo H-treated s19A in lane 1 and 2, respectively). For comparison, the lane 
containing PNGase F-treated protein from the same gel is also shown (lane 3). Open arrowhead, Endo 
H; filled arrowhead, PNGase F. (C) Schematic view of the activities of 
N-acetylglucosaminyltransferase I (GnTI) and Golgi α-mannosidase II (MII). Processing of the 
Glc3Man9GlcNAc2 precursor to Man5GlcNAc2 by α-glucosidase I, II and the class I α-mannosidases 
has been omitted for clarity as have the potential elaborations of the basic hybrid-type glycan. Key to 
symbols used to represent monosaccharide constituents in this and subsequent figures:  , Gal; ¡, 
GalNAc; , GlcNAc; {, Man; Ë, sialic acid; , Fuc. The linkage position is shown by the angle of 
the lines linking the sugar residues (vertical line, 2-link; forward slash, 3-link; horizontal line, 4-link; 
back slash, 6-link). Anomericity is indicated by full lines for β-bonds and broken lines for α-bonds. 
 
FIGURE 3. MALDI-TOF MS of N-linked glycans ([M+Na]+ ions) from s19A expressed in (A) HEK 
293T cells, (B) HEK 293T Lec36 cells, and (C) HEK 293T cells in the presence of 20 μM 
swainsonine. Spectra have been processed with the MaxEnt 2 function of MassLynx 4.1. Symbols as 
in the Figure 2 legend. 
 
FIGURE 4. Negative ion ESI-CID spectrum of isobaric (A) complex-type and (B) hybrid-type 
N-linked glycans ([M+H2PO4]- ions; m/z 1883.7) from s19A. The complex- and hybrid-type glycans 
were from s19A expressed in HEK 293T and HEK 293T Lec36 cells, respectively. Symbols as in the 
Figure 2 legend. Ion nomenclature follows the method of Domon and Costello (54).  
 
FIGURE 5.  Molecular basis of the Lec36 mutation. (A) Sequence of Golgi α-mannosidase II 
(MAN2A1) from HEK 293T Lec36 cells indicating the positions of the point mutation in MA1 
encoding G574E and the in frame deletion in MA2 resulting in the ΔILVQ deletion. (B) Mapping of 
the Lec36 mutations onto the crystal structure of D. melanogaster Golgi α-mannosidase II (PDB ID 
3CZN) complexed with zinc and oligomannose-type substrate(56). The box on the left shows the area 
of the active site containing the residue analogous to the Lec36 G574E substitution encoded by MA1. 
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 The active site comprises a loop, depicted in green, containing both the ligand binding 472Asp and the 
buried 476Gly (equivalent to 570Asp and 574Gly, repectively, of the human enzyme). The 476Gly Cα 
carbon is depicted as a red sphere. The box on the right highlights in red the region analogous to the 
ΔILVQ (995Gln996Lys997Leu998Asp) deletion encoded by MA2. The molecular graphics images were 
generated using PyMOL (DeLano Scientific, San Carlos, CA, U.S.A.). 
 
FIGURE 6.  Complementation of Golgi α-mannosidase II deficiency. Coomassie-stained 
SDS-PAGE gel run under reducing conditions showing undigested (−) and Endo H digested (+) s19A 
expressed alone in HEK 293T (sample 1) and Lec36 cells (sample 2), and of s19A co-expressed in 
HEK 293T Lec36 cells with wild-type Golgi α-mannosidase II (sample 3), the G574E substituted 
form of Golgi α-mannosidase II encoded by MA1 (sample 4) and the ΔILVQ-deleted form of Golgi 
α-mannosidase II encoded by MA2 (sample 5). Open arrowhead, Endo H. 
 
FIGURE 7. MALDI-TOF MS of N-linked glycans ([M+Na]+ ions) from s19A co-expressed in HEK 
293T Lec36 cells with wild-type Golgi α-mannosidase II (A), the G574E substituted form of Golgi 
α-mannosidase II encoded by MA1 (B) and the ΔILVQ-deleted form of Golgi α-mannosidase II 
encoded by MA2 (C). Symbols as in the Figure 2 legend. Spectra have been processed with the 
MaxEnt 3 function of MassLynx 4.1. 
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Candidate loss of 
function 
18−21 ~1 green very low 3 Loss of ricin 
receptors 
2−9 5−9 orange medium-normal 6 Toxin trafficking,  
processing or 
dislocation 
2−13 0.3−3 grey medium-normal 
(group I)  
~38 Toxin trafficking,  
processing or 
dislocation 
2−13 0.3−3 grey low-medium  
(group II) 
~20 Loss of ricin 
receptors 




a Fold resistance over parental (IC50 clone: IC50 HEK 293T); b Defined in Figure 1;  
c Determined by flow cytometry after binding Alexa Fluor 647-labelled ricin B chain; d Eight cell lines 
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